HAVE A CONVERSATION ABOUT IDELVION

We get it. The process of changing therapies can be just one more thing in your already busy life. That’s why we’ve made talking with your doctor about IDELVION simple. Review the topics below and check the ones you’d like to discuss with your doctor. Then schedule your appointment and bring this conversation-starter with you.

I’d like to talk about...

☐ Optimizing My Bleed Protection

I experienced ______ breakthrough bleeds last year.

In clinical studies, IDELVION delivered zero bleeds (median AsBR*) when dosed at 7 or 14 days.

Would the long-lasting bleed protection of IDELVION be a good fit for me?

☐ Extending My Dosing Schedule

I am currently infusing every ______ days.

IDELVION is the only Factor IX therapy FDA approved for up to 14-day dosing.†

Is IDELVION 7- or 14-day dosing an option for me?

☐ Raising My Steady-State FIX Levels

Some of the activities that I enjoy are ____________________________.

IDELVION maintained Factor IX trough levels of 21% with prophylactic use in clinical studies.‡

Would high and sustained factor levels with IDELVION give me the coverage I need for my lifestyle?

*Median annualized spontaneous bleeding rate.
†Once well-controlled (1 month without spontaneous bleeding on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.
‡Average FIX levels in prophylaxis with 7-day dosing over 92 weeks was 21% and 14-day dosing over 104 weeks was 13% in clinical trials.

Please see full Important Safety Information on next page and full prescribing information, including patient product information, on IDELVION.com.
IDELVION® Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rFIX-FP), is used to control and prevent bleeding episodes in people with hemophilia B. Your doctor might also give you IDELVION before surgical procedures. Used regularly as prophylaxis, IDELVION can reduce number of bleeding episodes.

IDELVION is administered by intravenous injection into the bloodstream, and can be self-administered or administered by a caregiver. Do not inject IDELVION without training and approval from your healthcare provider or hemophilia treatment center.

Tell your healthcare provider of any medical condition you might have, including allergies and pregnancy, as well as all medications you are taking. Do not use IDELVION if you know you are allergic to any of its ingredients, including hamster proteins. Tell your doctor if you previously had an allergic reaction to any FIX product.

Stop treatment and immediately contact your healthcare provider if you see signs of an allergic reaction, including a rash or hives, itching, tightness of chest or throat, difficulty breathing, lightheadedness, dizziness, nausea, or a decrease in blood pressure.

Your body can make antibodies, called inhibitors, against Factor IX, which could stop IDELVION from working properly. You might need to be tested for inhibitors from time to time. IDELVION might also increase the risk of abnormal blood clots in your body, especially if you have risk factors. Call your healthcare provider if you have chest pain, difficulty breathing, or leg tenderness or swelling.

In clinical trials for IDELVION, headache was the only side effect occurring in more than 1% of patients (1.8%), but is not the only side effect possible. Tell your healthcare provider about any side effect that bothers you or does not go away, or if bleeding is not controlled with IDELVION.

Please see full prescribing information for IDELVION, including patient product information.

You are also encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.


CSL Behring

Biotherapies for Life®

IDELVION is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC. IDELVION® is a registered trademark of CSL Behring Lengnau AG. Biotherapies for Life® is a registered trademark of CSL Behring LLC.

©2019 CSL Behring LLC 1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USA

www.CSLBehring.com www.IDELVION.com IDL-0286-JAN19